D. Kumar et al. / Steroids 80 (2014) 71–79
73
2.6.3. 1-(6-Deoxy-1,2:3,4-di-O-isopropylidene-
yl)-4-ethisterone-1,2,3-triazole (5c)
a
-
D
-galactopyranos-50-
CDCl3): 199.5, 171.3, 153.1, 137.1, 128.6, 128.1, 127.7, 123.7,
122.9, 111.9, 105.1, 82.2, 81.8, 81.1, 80.1, 72.2, 67.5, 53.6, 53.0,
48.9, 46.8, 38.5, 37.5, 36.1, 35.4, 33.8, 32.7, 32.5, 31.4, 26.7, 26.1,
23.4, 20.4, 17.3, 14.1 ppm; MS: m/z 648 [M+H]+; Anal. Calcd for
A solution of azide 3c (0.75 g, 2.6 mmol), and ethisterone 4
(0.9 g, 2.8 mmol) in presence of DIPEA (0.5 ml, 2.8 mmol) and CuI
(0.25 g, 1.3 mmol) in dry CH2Cl2 was sttired at room temparature
under argon atmosphenre for 12 h followed purification described
earlier afforded compound 5c. Yellowish solid (1.4 g, 92% yield);
C37H49N3O7: C, 68.60; H, 7.62; N, 6.49. Found: C, 68.86; H, 8.01;
N, 6.68.
[
a]
D = ꢁ16.2 (c 0.20 CHCl3); IR (KBr)
m
max: 3458, 3156, 2979,
2.6.6. 4-Ethisterone-1-(2,3,4,6-tetra-O-acetyl-b-
1,2,3-triazole(5f)
D-glucoopyranosyl)-
2940, 2869, 1667, 1384, 1068 cmꢁ1 1H NMR (300 MHz, CDCl3): d
;
7.57 (s, 1H, triazolyl-H), 5.69 (s, 1H, ethisterone-H), 5.49 (d,
J = 3.9 Hz, 1H, H-1), 4.65–4.60 (m, 2H, H-2 and H-3), 4.47–4.32
(m, 2H, H-4 and H-5), 4.22–4.12 (m, 2H, H-6), 2.38–2.30 (m, 6H,
ethisterone-H), 2.15–2.04 (m, 2H, ethisterone-H), 1.97–1.87 (m,
2H, ethisterone-H), 1.65–1.17 (m, 22H, 4 ꢂ CH3 of >C(CH3)2 and
ethisterone-H), 1.05 (s, 3H, ethisterone-CH3), 0.70 (m, 1H, ethister-
one-H), 0.47 (m, 1H, ethisterone-H); 13C NMR (75 MHz, CDCl3):
199.4, 171.3, 152.9, 123.6, 122.3, 109.8, 108.9, 96.1, 81.9, 71.1,
70.6, 70.3, 67.3, 53.2, 50.5, 48.8, 46.8, 38.5, 37.5, 36.2, 35.5, 33.8,
32.7, 32.5, 31.5, 25.9, 24.8, 24.3, 23.5, 20.5, 17.3, 14.1 ppm; MS:
m/z 598 [M+H]+; Anal. Calcd for C33H47N3O7: C, 66.31; H, 7.93; N,
7.03. Found: C, 65.99; H, 8.16; N, 7.40.
A solution of azide 3f (100 mg, 0.26 mmol), and ethisterone 4
(92 mg, 0.29 mmol) in presence of DIPEA (0.045 ml, 0.26 mmol)
and CuI (25 mg, 0.13 mmol) in dry CH2Cl2 was sttired at room tem-
parature under argon atmosphenre for 12 h followed purification
described earlier afforded compound 5f. White crystline (142 mg,
80% yield); IR (KBr)
mmax: 3436, 2926, 2857, 1756, 1662, 1370,
1038 cmꢁ1 1H NMR (300 MHz, CDCl3): d 7.70 (s,1H, triazolyl-H),
;
5.87 (d, J = 8.1 Hz, 1H), 5.69 (s, 1H), 5.44–5.41 (m, 2H), 5.24 (t,
J = 9.0 Hz, 1H), 4.31 (dd, J = 5.1 Hz, 12.6 Hz, 1H), 4.17–4.13 (m,
1H), 4.02 (d, J = 8.1 Hz, 1H), 2.44–2.29 (m, 5H), 2.07–1.82 (m,
17H), 1.60–1.05 (m, 17H), 0.70 (m, 1H), 0.37 (m, 1H); 13C NMR
(75 MHz, CDCl3): 199.4, 171.2, 170.3, 169.7, 169.3, 168.6, 154.2,
123.7, 119.6, 85.5, 82.1, 74.9, 72.5, 70.2, 67.6, 61.4, 53.3, 48.6,
46.7, 38.4, 37.6, 36.1, 35.5, 33.7, 32.7, 32.4, 31.4, 23.8, 20.6, 20.4,
20.0, 17.3, 14.0 ppm.
2.6.4. 4-Ethisterone-1-(methyl-2,3,4-tri-O-benzyl-6-deoxy-a-D-
glucopyranos-5-yl)-1,2,3-triazole (5d)
A solution of azide 3d (1.08 g, 2.2 mmol), and ethisterone 4
(0.75 g, 2.4 mmol) in presence of DIPEA (0.5 ml, 2.4 mmol) and
CuI (0.2 g, 1 mmol) in dry CH2Cl2 was sttired at room temparature
under argon atmosphenre for 12 h followed purification described
earlier afforded compound 5d. Yellowish solid (1.55 g, 88% yield);
2.6.7. 4-Ethisterone-1-(2,3,4,6-Tetra-O-benzoyl-b-
1,2,3-triazole (5g)
D-glucopyranosyl)-
A solution of azide 3g (1 g, 1.5 mmol), and ethisterone 4 (0.55 g,
1.7 mmol) in presence of DIPEA (0.35 ml, 1.7 mmol) and CuI
(0.15 g, 0.7 mmol) in dry CH2Cl2 was sttired at room temparature
under argon atmosphenre for 12 h followed purification described
earlier afforded compound 5g. Yellowish solid (1.2 g, 82% yield);
[
a]
D = ꢁ18.8 (c 0.20 CHCl3); IR (KBr)
m
max: 3438, 3147, 3088,
3062, 3030, 2939, 2857, 1667, 1359, 1055 cmꢁ1
;
1H NMR
(300 MHz, CDCl3): d 7.44 (s, 1H, triazolyl-H), 7.33–7.31 (m, 15H,
Ar–H), 5.68 (s, 1H, ethisterone-H), 4.99–4.89 (m, 2H, OCH2Ph),
4.82–4.68 (m, 3H, H-1 and OCH2Ph), 4.62–4.54 (m, 4H, OCH2Ph
and H-6), 4.00–3.97 (m, 2H, H-3 and H-5), 3.43–3.40 (m, 1H, H-
2), 3.16–3.12 (m, 4H, OCH3 and H-4), 2.61 (s, 1H, ethisterone-H),
2.37–2.23 (m, 5H, ethisterone-H), 2.12–2.04 (m, 1H, ethisterone-
H), 1.93–1.86 (m, 3H, ethisterone-H), 1.57–1.47 (m, 5H, ethister-
one-H), 1.38–1.25 (m, 2H, ethisterone-H), 1.16 (s, 3H, ethister-
one-CH3), 1.04 (s, 3H, ethisterone-CH3), 0.69–0.65 (m, 1H,
ethisterone-H), 0.47–0.40 (m, 1H, ethisterone-H); 13C NMR
(75 MHz, CDCl3): 199.3, 171.0, 153.3, 138.2, 137.7, 128.6, 128.4,
128.0, 127.9, 127.7, 123.7, 122.4, 97.9, 82.0, 81.6, 79.9, 78.0, 75.7,
74.9, 73.4, 69.1, 55.2, 53.2, 50.7, 48.7, 46.7, 38.4, 37.7, 36.1, 35.5,
33.7, 32.6, 32.6, 31.4, 23.6, 20.5, 17.3, 14.1 ppm; MS: m/z 802
[M+H]+; Anal. Calcd for C49H59N3O7: C, 73.38; H, 7.41; N, 5.24.
Found: C, 73.02; H, 7.63; N, 4.93.
[a
]
D = ꢁ23.2 (c 0.20 CHCl3); IR (KBr)
m
max: 3446, 3158, 3064,
3033, 2926, 2854, 1729, 1663, 1316, 1092 cmꢁ1
;
1H NMR
(300 MHz, CDCl3): d 8.01–7.70 (m, 9H, Ar–H and triazolyl-H),
7.55–7.22 (m, 12H, Ar–H), 6.25 (d, J = 9.6 Hz, 1H, H-1), 6.08 (t,
J = 9.6 Hz, 1H, H-3), 5.97–5.83 (m, 2H, H-2 and H-4), 5.66 (s, 1H,
ethisterone-H), 4.66 (d, J = 10.5 Hz, 1H, H-5), 4.52–4.48 (m, 2H,
H-6), 2.52 (s, 1H, ethisterone-H), 2.27–2.21 (m, 5H, ethisterone-
H), 2.02–1.66 (m, 4H, ethisterone-H), 1.54–1.39 (m, 1H, ethister-
one-H), 1.34–1.25 (m, 7H, ethisterone-H), 1.10 (s, 3H,
ethisterone-CH3), 0.99 (s, 3H, ethisterone-CH3), 0.37 (m, 1H, ethis-
terone-H), 0.16 (m, 1H, ethisterone-H); 13C NMR (75 MHz, CDCl3):
199.3, 171.2, 166.0, 165.4, 165.0, 164.7, 154.4, 133.7, 133.4, 133.2,
129.8, 129.7, 129.6, 128.4, 127.9, 123.6, 119.7, 86.0, 82.3, 75.5,
72.9, 70.9, 68.8, 62.6, 52.9, 48.4, 46.7, 38.4, 37.8, 36.0, 35.6, 33.8,
32.7, 32.3, 31.3, 23.9, 20.4, 17.2, 14.0 ppm; MS: m/z 934 [M+H]+;
Anal. Calcd for C55H55N3O11: C, 70.72; H, 5.94; N, 4.50. Found: C,
70.38; H, 5.67; N, 4.71.
2.6.5. 4-Ethisterone-1-(3-O-benzyl-6-deoxy-1,2-O-isopropylidene-
-glucofuranos-5-yl)-1,2,3-triazole (5e)
A solution of azide 3e (305 mg, 0.9 mmol), and ethisterone 4
a-
D
2.6.8. 4-Ethisterone-1-(2,3,4-tri-O-acetyl-b-
triazole (5h)
D-xylopyranosyl)-1,2,3-
(312 mg, 1 mmol) in presence of DIPEA (0.171 ml, 1 mmol) and
CuI (86 mg, 0.45 mmol) in dry CH2Cl2 was sttired at room tempar-
ature under argon atmosphenre for 12 h followed purification de-
scribed earlier afforded compound 5e. Yellowish solid (550 mg,
A solution of azide 3h (98 mg, 0.32 mmol), and ethisterone 4
(111 mg, 0.35 mmol) in presence of DIPEA (0.06 ml, 0.35 mmol)
and CuI (30 mg, 0.16 mmol) in dry CH2Cl2 was sttired at room tem-
parature under argon atmosphenre for 10 h followed purification
described earlier afforded compound 5h. Yellowish solid
93% yield); [
a]
D = ꢁ17.0 (c 0.19 CHCl3); IR (KBr)
mmax: 3316, 2973,
2936, 2886, 1674, 1385, 1080 cmꢁ1
;
1H NMR (300 MHz, CDCl3): d
7.44 (s, 1H, triazolyl-H), 7.33–7.26 (m, 5H, Ar–H), 5.92 (d,
J = 3.3 Hz, 1H, H-1), 5.69 (s, 1H, ethisterone-H), 4.73–4.54 (m, 4H,
OCH2Ph, H-2, H-4), 4.43–4.37 (m, 2H, H-6), 4.12–4.07 (m, 1H, H-
5), 4.84 (d, J = 5.4 Hz, H-3), 3.02 (d, J = 5.4 Hz, -OH at C-5), 2.87 (s,
1H, ethisterone-H), 2.42–2.25 (m, 5H, ethisterone-H), 2.14–2.07
(m, 1H, ethisterone-H), 1.96–1.86 (m, 3H, ethisterone-H), 1.63–
1.25 (m, 13H, 2 ꢂ CH3 of > C(CH3)2 and ethisterone-H), 1.17 (s,
3H, ethisterone-CH3), 1.05 (s, 3H, ethisterone-CH3), 0.74 (m, 1H,
ethisterone-H), 0.47 (m, 1H, ethisterone-H); 13C NMR (75 MHz,
(175 mg, 88% yield); [
a
]
D = ꢁ12.5 (c 0.20 CHCl3); IR (KBr) mmax
:
3472, 3148, 2927, 2856, 1759, 1666, 1371, 1038 cmꢁ1
;
1H NMR
(300 MHz, CDCl3): d 7.59 (s,1H, triazolyl-H), 5.76 (d, J = 8.4 Hz,
1H, H-1), 5.69 (s, 1H, ethisterone-H), 5.44–5.34 (m, 2H, H-2 and
H-3), 5.16–5.14 (m, 1H, H-4), 4.30 (dd, J = 5.4, 11.1 Hz, 1H, HA-5),
3.62–3.65 (m, 1H, HB-5), 2.57 (s, 1H, ethisterone-H), 2.38–2.24
(m, 5H, ethisterone-H), 2.07–2.04 (m, 11H, 3 ꢂ OAc, 2H, ethister-
one-H), 1.92–1.84 (m, 2H, ethisterone-H), 1.60–1.34 (m, 7H,
ethisterone-H), 1.17 (s, 3H, ethisterone-CH3), 1.05 (s, 3H,